"If not dead, not healthy": Niacin full results in HPS2-THRIVE aired at ACC
Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, with approximately 30 adverse events per 1000 treated patients. (Source: theHeart.org)
Source: theHeart.org - March 10, 2013 Category: Cardiology Source Type: news
Big Bucks, No Benefits with Many Drugs
(MedPage Today) -- Cardiologists meeting in San Francisco were told that extended-release niacin has no measurable benefits in heart disease and many risks. But niacin is not the only popular treatment that piles up profits without proof. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 10, 2013 Category: Cardiology Source Type: news
Niacin Full Results in HPS2-THRIVE Aired at ACCNiacin Full Results in HPS2-THRIVE Aired at ACC
Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, w Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
ACC: HPS2-THRIVE May Signal the End for Niacin (CME/CE)
SAN FRANCISCO (MedPage Today) -- Results from a landmark study of specially formulated niacin in more than 25,000 high-risk patients appears to have extinguished any clinical role for niacin to reduce the risk of cardiovascular events in these patients, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 9, 2013 Category: Cardiology Source Type: news
Serious side effects seen with failed Merck niacin drug
SAN FRANCISCO (Reuters) - Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients. (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Niacin Won't Help, May Harm Heart Patients
Taking the B vitamin offered no benefit in lowering cardiac deaths or heart attacks, researchers say
Source: HealthDay
Related MedlinePlus Pages: B Vitamins, Cholesterol, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 9, 2013 Category: Consumer Health News Source Type: news
Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
Dateline City:
SAN FRANCISCO
SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers from the Clinical Trial Service Unit at
Oxford University presented results from the HPS2-THRIVE (Heart Protection
Study 2-Treatment of HDL to Reduce the Incidence
of Vascular Events) study of TREDAPTIVE™(extended-release
niacin/laropiprant) during a late-breaking clinical trials session at
the American College of Cardiology 62nd Annual Scientific
Ses...
Source: Merck.com - Research and Development News - March 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Nicotinic Acid Under Review by EMA, Following HPS2-THRIVENicotinic Acid Under Review by EMA, Following HPS2-THRIVE
Agencies worldwide suspended the marketing of niacin/laropiprant products in January; the new announcement from the European regulator is extending the review to products containing only nicotinic acid (or related substances). Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
EMA launches review of nicotinic acid on eve of HPS2-THRIVE late-breaker
Agencies worldwide suspended the marketing of niacin/laropiprant products in January; the new announcement from the European regulator is extending the review to products containing only nicotinic acid (or related substances). (Source: theHeart.org)
Source: theHeart.org - March 8, 2013 Category: Cardiology Source Type: news
ACC: Eyes Are on Watchman, Niacin
SAN FRANCISCO (MedPage Today) -- The Watchman left atrial appendage closure device and details from a failed niacin trial will be in the spotlight when the American College of Cardiology meeting kicks off Saturday. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 7, 2013 Category: Cardiology Source Type: news
Side-Effects Cause A Quarter Of Heart Patients To Stop Treatment In The HPS2-THRIVE Trial
The largest randomised study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side-effects when it is combined with statin treatment. Results from the HPS2-THRIVE study (Heart Protection Study 2 - Treatment of HDL to Reduce the Incidence of Vascular Events), including the reasons patients stopped the study treatment, were published online yesterday (Wednesday) in the European Heart Journal [1]... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2013 Category: Consumer Health News Tags: Cholesterol Source Type: news
Niacin-statin combo tied to skin, muscle side effects
NEW YORK (Reuters Health) - One-quarter of people taking niacin and statins as part of a four-year-long heart study dropped out early, often for medical reasons tied to niacin's side effects, a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Niacin-Statin Combo Tied to Skin, Muscle Side Effects
One-quarter of people taking niacin and statins as part of a four-year-long heart study dropped out early, often for medical reasons tied to niacin's side effects, a new study suggests.Source: Reuters Health
Related MedlinePlus Pages: B Vitamins, Cholesterol, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 27, 2013 Category: Consumer Health News Source Type: news
Side Effects Dim Niacin Promise (CME/CE)
(MedPage Today) -- A highly significant increase in adverse events, in particular myopathy, appears to have been a driving force behind the decision to shut down a pivotal trial of Tredaptive, the agent that many hoped would improve niacin tolerance. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 27, 2013 Category: Cardiology Source Type: news
Niacin Adverse Events in HPS2-THRIVENiacin Adverse Events in HPS2-THRIVE
Extended-release niacin and laropiprant added to simvastatin were associated with a significantly increased risk of definite myopathy. Interestingly, the risk of myopathy was significantly higher in randomized patients from China than in patients from Europe. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
